|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2010-11-8
|
|
pubmed:abstractText |
Gemcitabine (2',2'-difluorodeoxycytidine) administration after resection of pancreatic cancer improves both disease-free survival (DFS) and overall survival (OS). Deoxycytidine kinase (dCK) mediates the rate-limiting catabolic step in the activation of gemcitabine. The authors of this report studied patient outcomes according to the expression of dCK after a postoperative gemcitabine-based chemoradiation regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5200-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20669326-Adenocarcinoma,
pubmed-meshheading:20669326-Adult,
pubmed-meshheading:20669326-Aged,
pubmed-meshheading:20669326-Aged, 80 and over,
pubmed-meshheading:20669326-Chemotherapy, Adjuvant,
pubmed-meshheading:20669326-Combined Modality Therapy,
pubmed-meshheading:20669326-Deoxycytidine,
pubmed-meshheading:20669326-Deoxycytidine Kinase,
pubmed-meshheading:20669326-Disease-Free Survival,
pubmed-meshheading:20669326-Female,
pubmed-meshheading:20669326-Humans,
pubmed-meshheading:20669326-Male,
pubmed-meshheading:20669326-Middle Aged,
pubmed-meshheading:20669326-Pancreatic Neoplasms,
pubmed-meshheading:20669326-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepato-Pancreatology, Free University of Brussels, Brussels, Belgium. rmarecha@ulb.ac.be
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
